Posted from: Tuesday, September 05, 2017 - 04:20 PM - Present

Expanded Indication for Kalydeco

July 31, 2017 – The U.S. FDA has approved an expanded indication for Kalydeco® (ivacaftor), manufactured by Vertex, to treat cystic-fibrosis patients two years of age and older who have any of five additional mutations that cause splicing defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Recommended dosage for patients six years of age and older is one 159mg tablet per day. Smaller doses of powdered Kalydeco mixed into soft foods should be used for patients younger than six years old. Originally approved in 2012 for the treatment of cystic fibrosis in patients with one of 23 other specific mutations, Kalydeco can now be used to treat an estimated additional 600 patients.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

 

Last Updated Wednesday, September 20, 2017 - 01:13 AM.